



(51) International Patent Classification:

A61K 38/47 (2006.01) *A61K 31/095* (2006.01)
A61K 38/48 (2006.01) *A61K 31/21* (2006.01)
A61K 38/54 (2006.01) *A61P 35/00* (2006.01)

FELQUER, Fernando [AU/AU]; 43 Cedar Crescent,
Glenside, South Australia 5065 (AU). **BRANDT, Ralf**
[DE/AU]; 6 Madigan Court, Greenwith, South Australia
5125 (AU).

(21) International Application Number:

PCT/AU2010/001403

(74) **Agent: GRIFFITH HACK**; Level 3, 509 St Kilda Road,
Melbourne, Victoria 3004 (AU).

(22) International Filing Date:

22 October 2010 (22.10.2010)

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2009905147 22 October 2009 (22.10.2009) AU
 2010902655 17 June 2010 (17.06.2010) AU

(71) **Applicant** (*for all designated States except US*):
PROPANC PTY LTD [AU/AU]; 576 Swan Street, Rich-
mond, Victoria 3121 (AU).


(72) Inventors; and

(75) **Inventors/Applicants** (*for US only*): **KENYON, Julian, Norman** [GB/GB]; Beechwood, Embley Lane, East Wel-
low, Romsey Hampshire SO51 6DN (GB). **CLAYTON, Paul, Rodney** [GB/GB]; 1 Church Close, Church Street,
Epsom Surrey KT17 4PT (GB). **TOSH, David** [IE/GB];
C/o Centre for Regenerative Medicine, Department of Bi-
ology and Biochemistry, University of Bath, Claverton
Down Bath and North East Somerset BA2 7AY (GB).

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) **Title:** A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT



(57) **Abstract:** The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumour cell to enhance cell-to-cell adhesion of tumour cells, effect proteolysis of tumour cells, or induce tumour cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumour cells.

WO 2011/047434 A1



Published:

— *with international search report (Art. 21(3))*